Lou Smith 🍀 @smith348572 Most retail investors still misunderstand how capital markets operate. When a company is preparing to evolve from a micro-cap clinical stage biotech into a true commercial stage oncology company, finding a very good investment banker becomes one of the top strategic priorities. And that is exactly the stage $NWBO is entering right now.
$NWBO is transitioning from the “minor leagues” to the “major leagues,” and serious investment bankers will immediately require two things: http://1.An Annual Shareholders’ Meeting held as soon as possible, and http://2.An increase in authorized shares.
Why? Because no reputable banker will advise or engage unless the company’s capital structure gives them room to execute. Bankers don’t work for free, and they cannot build transactions, approach strategic partners, or engage institutions when the authorized share count is too tight for flexible financing or partnership structures.
To operate at the commercial level, $NWBO must have: •a flexible equity structure •capacity for institutional allocations •room for strategic investment deals •capital to support commercial launch (working capital) •equity tools that bankers need to structure transactions •sufficient authorized shares to satisfy institutional minimums
In other words: Fix the structure first, then the bankers can execute.
And here is the key point most people miss: Serious Bankers Only Step In When Approval Looks Highly Certain
Investment banks are not gamblers. They only engage when they believe the regulatory outcome is overwhelmingly positive.
So if bankers are advising $NWBO right now on: •timing of the ASM •increasing authorized shares •capital structure optimization •commercial-stage financial planning
it means only one thing:
They believe approval is extremely likely.
Banks protect their reputations. They conduct deep due diligence. They analyze: •Phase 3 data •the JAMA publication •MHRA precedent •Sawston’s manufacturing approvals •CMC readiness •MAA validation •the pattern of MHRA interactions
If approval were uncertain, bankers simply would not waste time. Their involvement is itself a strong confidence signal.
The ASM + share increase are not “dilution signs”, they’re required steps for a company preparing for commercial operations, strategic partnerships, and institutional financing.
This is exactly what a company looks like right before it moves into the major leagues. 5:53 PM · Nov 21, 2025 · 5,171 Views
Most retail investors still misunderstand how capital markets operate. When a company is preparing to evolve from a micro-cap clinical stage biotech into a true commercial stage oncology company, finding a very good investment banker becomes one of the top strategic priorities.…
Market Data 
Markets 
AI
